English
Regional settings| Spread | 0.0284 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 0.01 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 3.8858 |
| Open | 3.7958 |
| 1-Year Change | 182.07% |
| Day's Range | 3.6058 - 3.9358 |
Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells. ALRN-6924 acts as an agent to reduce the toxic side effects of chemotherapy in the bone marrow of cancer patients without adversely impacting the anti-cancer activity of chemotherapy against p53-mutant tumors.
BRIEF: For the nine months ended 30 September 2021, Aileron Therapeutics Inc revenues was not reported. Net loss increased 20% to $19.4M. Higher net loss reflects Research and development increase of 38% to $12.1M (expense), Stock-based Compensation in SGA increase of 20% to $1.3M (expense), General and administrative increase of 1% to $6.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.51 to -$0.22.
